Program
ASK-120067
Also written as “ASK120067”, “ASKC202+ Limertinib” and “Rifampicin; ASK120067”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Beijing Aosaikang Pharmaceutical.
Furthest: phase 3, since Oct 12, 20195 company-led studies, 2 open or runningNext primary completion: Oct 31, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Beijing Aosaikang Pharmaceutical | 52 open or running | phase 3since Oct 12, 2019 | Apr 10, 2018 | Oct 31, 2027phase 3 · NCT07109531 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 10, 2018First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT03502850 · 507 enrolled · China
- Oct 12, 2019Phase 3 study in Carcinoma, Non-Small-Cell LungNCT04143607 · 337 enrolled · China
- Apr 20, 2020Phase 1 study in Carcinoma, Non-Small-Cell LungNCT04360915 · 24 enrolled · China
- Nov 11, 2022Phase 1 study in Carcinoma, Non-Small-Cell LungNCT05631678 · 48 enrolled · China
- Jul 31, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07109531 · 286 planned · China
Ahead
- Oct 31, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07109531
TargetBeta
EGFR →read by rule
“Limertinib (ASK120067) is a novel third-generation EGFR tyrosine kinase inhibitor with favorable central nervous system penetration and encouraging intracranial antitumor activity.”study text, by rule · the study
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| pimurutamab | Fosun Pharma | phase 3 | 17 |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 16 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 11 |
| andamertinibrule | avistone-biotechnology-co-ltd | phase 3 | 10 |
| becotatug vedotinrule | lepu-biopharma-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 7 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| zipalertinibrule | Otsuka | phase 3 | 4 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07109531Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Oct 31, 2027 | 286 |
| NCT05631678Carcinoma, Non-Small-Cell Lung · China | 1 | Completed | Aug 3, 2022 | 48 |
| NCT04360915Carcinoma, Non-Small-Cell Lung · China | 1 | Completed | Dec 30, 2019 | 24 |
| NCT04143607Carcinoma, Non-Small-Cell Lung · China | 3 | Active, not recruiting | Mar 31, 2024 | 337 |
| NCT03502850Carcinoma, Non-Small-Cell Lung · China | 2 | UNKNOWN | Jan 2021 | 507 |
How it is read
Names in the registry
- “ASK120067”, 3 entries
- “ASKC202+ Limertinib”, 1 entry
- “Rifampicin; ASK120067”, 1 entry
- “ASK120067;itraconazole”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.